Access + Impact: Insights on Patient Services & Market Access
At eMAX Health, we believe better outcomes begin with smarter infrastructure. Access + Impact is where we share perspectives from across our enterprise and cover everything from scalable patient support programs to commercialization strategy and market access innovation.
Explore thought leadership, technology updates, and real-world best practices that help manufacturers deliver access, affordability, and adherence at every stage of the brand lifecycle.
The New Normal of Iterative Market Access: Why Static Annual Research is Dead
Static annual market access research can’t keep pace with today’s rapid policy, pricing, and payer shifts. Learn why high-performing pharmaceutical teams are adopting iterative, agile insight loops, and how this new model is transforming launch and portfolio strategy.
A New Federal Committee on Care Financing: What It Means for Patient Services
CMS’s new Healthcare Advisory Committee targets efficiency and outcomes. Here’s how patient services can adapt now to reduce burden and speed access.
A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access
HHS and CMS have formed a new Healthcare Advisory Committee to reshape how federal payers finance and deliver care. Learn how this could impact pharma market access—and why agile insight platforms like MAVA™ are essential to adapt.
Hybrid Patient Support Models That Put You in Control
Hybrid and insourced patient support models give pharmaceutical manufacturers the flexibility and control missing in fully outsourced hubs. With HealthPACER® and expert operational support, eMAX Health Patient Services helps brands streamline access, strengthen compliance, and design scalable patient services that adapt to market demands.
Why Flexibility Matters in Pharma Support Programs
Many pharma manufacturers are stuck between outdated patient support models and rising access challenges. In this post, eMAX Health Patient Services explores how flexible strategies like hybrid support models, scalable tech platforms, and alternative funding solutions, can help manufacturers modernize their Patient Assistance Programs and improve outcomes across the product lifecycle.
Is your PSP Program Future-Ready?
As policy shifts, pricing pressures, and compliance demands reshape the healthcare landscape, traditional Patient Support Programs (PSPs) are struggling to keep up. In this post, eMAX Health Patient Services explores why manufacturers must reimagine their PSP strategies to ensure sustainability, regulatory resilience, and brand alignment in today’s high-stakes environment.
Access is changing. The question is whether patient services will keep pace.
The launch of FluMist Home signals a major shift in healthcare delivery, where patients can complete the full treatment journey without entering a clinic. In this post, Mary Lynn Kelley, President of eMAX Health Patient Services, explores what this means for specialty therapies and patient access programs. From benefit verification and affordability support to compliance and safety monitoring, the future of patient services will require flexible, tech-enabled models that can keep pace with evolving care settings.
MFN Deadline Is Here: How Pharma Teams Can Respond Strategically
The Most-Favored-Nation Executive Order deadline has passed. Learn how pharma teams can use MAVA®, Elasticity™, Contracting ROI, and SCORE™ to adapt pricing strategy, validate assumptions, and stay ahead of regulatory enforcement.
From Opinion to Precision: How Elasticity™ Aligns Pricing and Value Strategy
Discover how Elasticity™, built into the MAVA® platform, helps Commercial and Medical teams model real-world pricing and value scenarios side by side. Align internal stakeholders, quantify value, and validate pricing strategy before launch.
Rebate Strategy Decisions Just Got Easier | Contracting ROI with MAVA®
Discover how MAVA™ by eMAX Health helps pharma teams model rebate ROI, forecast market access impact, and make smarter contracting decisions using real payer claims data. Join our expert panel of 5,000+ healthcare leaders shaping pharmaceutical access strategy.